Komori
Other Disclosures4576D.Western Therapeutics Institute, Inc.Pharmaceuticals

Notice Regarding the Publication of an Analyst Report on Our Company by 株式会社エンヴァリス

株式会社エンヴァリス published an analyst report on us, and we announced plans to continue updating it in line with future earnings releases.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Our analyst report
Applicable field (uses covered by this announcement)

Investor information services, corporate research, and equity research

Launch date10 August 2026 (announced the start of publication; the report has already been published)
Relationship between the counterparty and the company
D.Western Therapeutics Institute, Inc.4576
Relationship with the Company

株式会社エンヴァリス prepares and publishes the analyst report at our request. Capital and personnel relationships: Not disclosed

Counterparty株式会社エンヴァリス

An independent equity research platform that provides corporate research reports in Japanese, English, and Chinese and disseminates information to domestic and overseas institutional and individual investors. Reports are distributed through financial information platforms including Bloomberg, FactSet, Factiva, and AlphaSense. Location, representative, capital, and year established: Not disclosed

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Financial information platforms including Bloomberg, FactSet, Factiva, and AlphaSense (listed as distribution channels)

Announced details
ItemDetails
Names of Products / Services CoveredOur analyst report
Counterparty株式会社エンヴァリス
Counterparty overviewAn independent equity research platform that provides corporate research reports in Japanese, English, and Chinese and disseminates information to domestic and overseas institutional and individual investors. Reports are distributed through financial information platforms including Bloomberg, FactSet, Factiva, and AlphaSense. Location, representative, capital, and year established: Not disclosed
Relationship with the Company株式会社エンヴァリス prepares and publishes the analyst report at our request. Capital and personnel relationships: Not disclosed
Launch date10 August 2026 (announced the start of publication; the report has already been published)
Applicable areaInvestor information services, corporate research, and equity research
SourceFinancial information platforms including Bloomberg, FactSet, Factiva, and AlphaSense (listed as distribution channels)
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To deepen the understanding of our business activities, financial position, and medium- to long-term growth potential among domestic and overseas institutional and individual investors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Publication of an Analyst Report on Our Company by 株式会社エンヴァリス | D.Western Therapeutics Institute, Inc. (4576) timely disclosure | Komori